LLY

1,013.62

+2.58%↑

JNJ

230.14

+1.18%↑

ABBV

214.4

+2.42%↑

UNH

392.17

+1.15%↑

AZN

185.66

+0.71%↑

LLY

1,013.62

+2.58%↑

JNJ

230.14

+1.18%↑

ABBV

214.4

+2.42%↑

UNH

392.17

+1.15%↑

AZN

185.66

+0.71%↑

LLY

1,013.62

+2.58%↑

JNJ

230.14

+1.18%↑

ABBV

214.4

+2.42%↑

UNH

392.17

+1.15%↑

AZN

185.66

+0.71%↑

LLY

1,013.62

+2.58%↑

JNJ

230.14

+1.18%↑

ABBV

214.4

+2.42%↑

UNH

392.17

+1.15%↑

AZN

185.66

+0.71%↑

LLY

1,013.62

+2.58%↑

JNJ

230.14

+1.18%↑

ABBV

214.4

+2.42%↑

UNH

392.17

+1.15%↑

AZN

185.66

+0.71%↑

Kodu・Aktsiate loetelu・Simulations Plus Inc

Simulations Plus Inc

Avatud

SektorTervishoid

13.98 2.27

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

13.4

Max

14.08

Põhinäitajad
By Trading Economics
Sissetulek	3.9M 4.5M
Müük	5.9M 24M
Aktsiakasum	0.35
Dividenditootlus	0.48
Kasumimarginaal	18.669
Töötajad	212
EBITDA	4.9M 7.2M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+19.94% upside

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	0.48% 2.34%
Järgmine tulemuste avaldamine	13. juuli 2026

Turustatistika
By TradingEconomics
Turukapital	46M 297M
Eelmine avamishind	11.71
Eelmine sulgemishind	13.98

Uudiste sentiment

By Acuity

50%

157 / 345 Pingereas Healthcare

Simulations Plus Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

18. mai 2026, 23:10 UTC

Kuumad aktsiad

Stocks to Watch: Agilysys, XP

18. mai 2026, 18:44 UTC

Suurimad hinnamuutused turgudel

Claritev Shares Recover After Comments About DOJ

18. mai 2026, 23:55 UTC

Tulu

Review & Preview: Earnings' Last Gasp -- Barrons.com

18. mai 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18. mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

18. mai 2026, 23:37 UTC

Market Talk

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

18. mai 2026, 22:31 UTC

Omandamised, ülevõtmised, äriostud

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

18. mai 2026, 22:30 UTC

Omandamised, ülevõtmised, äriostud

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

18. mai 2026, 22:30 UTC

Omandamised, ülevõtmised, äriostud

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

18. mai 2026, 22:25 UTC

Omandamised, ülevõtmised, äriostud

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

18. mai 2026, 22:24 UTC

Omandamised, ülevõtmised, äriostud

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

18. mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18. mai 2026, 20:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Financial Services Roundup: Market Talk

18. mai 2026, 20:25 UTC

Tulu

Correct: XP 1Q Total Client Assets BRL1.53T

18. mai 2026, 20:23 UTC

Tulu

XP 1Q Total Client Assets BRL1.53B

18. mai 2026, 20:19 UTC

Tulu

XP 1Q Adj EPS BRL2.49 >XP

18. mai 2026, 20:19 UTC

Tulu

XP 1Q Rev BRL4.73B >XP

18. mai 2026, 19:10 UTC

Market Talk

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

18. mai 2026, 19:00 UTC

Tulu

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

18. mai 2026, 18:52 UTC

Market Talk

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

18. mai 2026, 18:17 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

18. mai 2026, 17:22 UTC

Market Talk

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

18. mai 2026, 16:57 UTC

Omandamised, ülevõtmised, äriostud

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

18. mai 2026, 16:57 UTC

Market Talk

Global Energy Roundup: Market Talk

18. mai 2026, 16:57 UTC

Market Talk

Commodities Higher as Traders Want Physical Assets -- Market Talk

18. mai 2026, 16:54 UTC

Omandamised, ülevõtmised, äriostud

Vinci Doesn't Set Out Financial Details of Deal

18. mai 2026, 16:50 UTC

Omandamised, ülevõtmised, äriostud

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

18. mai 2026, 16:49 UTC

Omandamised, ülevõtmised, äriostud

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

18. mai 2026, 16:49 UTC

Omandamised, ülevõtmised, äriostud

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

18. mai 2026, 16:48 UTC

Omandamised, ülevõtmised, äriostud

Vinci Buys Canada's Modern Group of Companies

Võrdlus sarnastega

Hinnamuutus

Simulations Plus Inc Prognoos

Hinnasiht

By TipRanks

19.94% tõus

12 kuu keskmine prognoos

Keskmine 16 USD 19.94%

Kõrge 16 USD

Madal 16 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Simulations Plus Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Simulations Plus Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

157 / 345 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.